Corcept Therapeutics Statistics
Share Statistics
Corcept Therapeutics has 105.5M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 105.5M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 81.5% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,628 |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 12.29M, so 11.65% of the outstanding
shares have been sold short.
| Short Interest | 12.29M |
| Short % of Shares Out | 11.65% |
| Short % of Float | 16.31% |
| Short Ratio (days to cover) | 5.11 |
Valuation Ratios
The PE ratio is 37.23 and the forward
PE ratio is 20.58.
Corcept Therapeutics's PEG ratio is
1.15.
| PE Ratio | 37.23 |
| Forward PE | 20.58 |
| PS Ratio | 7.71 |
| Forward PS | 3.2 |
| PB Ratio | 7.65 |
| P/FCF Ratio | 26.55 |
| PEG Ratio | 1.15 |
Financial Ratio HistoryEnterprise Valuation
Corcept Therapeutics has an Enterprise Value (EV) of 5.08B.
| EV / Sales | 7.53 |
| EV / EBITDA | 37.1 |
| EV / EBIT | 25.65 |
| EV / FCF | 25.94 |
Financial Position
The company has a current ratio of 3.35,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.35 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | 0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 20.56% and Return on Invested Capital is 17.09%.
| Return on Equity | 20.56% |
| Return on Assets | 16.62% |
| Return on Invested Capital | 17.09% |
| Revenue Per Employee | $1,350,080 |
| Profits Per Employee | $279,466 |
| Employee Count | 500 |
| Asset Turnover | 0.8 |
| Inventory Turnover | 0.88 |
Taxes
| Income Tax | 20.28M |
| Effective Tax Rate | 12.56% |
Stock Price Statistics
The stock price has increased by 209.22% in the
last 52 weeks. The beta is 0.21, so Corcept Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.21 |
| 52-Week Price Change | 209.22% |
| 50-Day Moving Average | 65.53 |
| 200-Day Moving Average | 53.13 |
| Relative Strength Index (RSI) | 55.88 |
| Average Volume (20 Days) | 1,604,440 |
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 675.04M
and earned 139.73M
in profits. Earnings per share was 1.35.
| Revenue | 675.04M |
| Gross Profit | 664.16M |
| Operating Income | 136.95M |
| Net Income | 139.73M |
| EBITDA | 136.95M |
| EBIT | 136.95M |
| Earnings Per Share (EPS) | 1.35 |
Full Income StatementBalance Sheet
The company has 127.67M in cash and 6.94M in
debt, giving a net cash position of 120.73M.
| Cash & Cash Equivalents | 127.67M |
| Total Debt | 6.94M |
| Net Cash | 120.73M |
| Retained Earnings | 543.74M |
| Total Assets | 840.55M |
| Working Capital | 330.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 198.07M
and capital expenditures -2.17M, giving a free cash flow of 195.9M.
| Operating Cash Flow | 198.07M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | 195.9M |
| FCF Per Share | 1.9 |
Full Cash Flow StatementMargins
Gross margin is 98.39%, with operating and profit margins of 20.29% and 20.7%.
| Gross Margin | 98.39% |
| Operating Margin | 20.29% |
| Pretax Margin | 23.92% |
| Profit Margin | 20.7% |
| EBITDA Margin | 20.29% |
| EBIT Margin | 20.29% |
| FCF Margin | 29.02% |
